Ticagrelor versus aspirin 2 years after coronary bypass: Observational analysis from the TARGET trial. Issue 7 (9th April 2022)

• Record Type: Journal Article
• Authors: Kulik, Alexander; Abreu, Amy M.; Boronat, Viviana; Kouchoukos, Nicholas T.; Ruel, Marc
• Is Part Of: Journal of cardiac surgery. Volume 37:Issue 7(2022)
• Page Start: 1969
• Page End: 1977
• Publication Date: 2022-04-09
• Subjects: antiplatelet therapy -- coronary artery bypass graft (CABG) surgery -- coronary artery disease -- graft patency; Heart -- Surgery -- Periodicals; 617.412005
• DOI: 10.1111/jocs.16492
• Languages: English
• ISSNs: 0886-0440

Abstract

Abstract: Background: Compared to conventional aspirin therapy, ticagrelor did not improve vein graft patency 1 year after coronary bypass surgery (CABG) in the ticagrelor antiplatelet therapy to reduce graft events and thrombosis (TARGET) trial. However, it is unknown whether ticagrelor may impact graft patency long‐term following surgery. Methods: In the TARGET multicenter trial, 250 CABG patients were randomized to aspirin 81 mg or ticagrelor 90 mg twice daily. In this observational analysis, 2 years after surgery, vein graft occlusion and clinical events were compared among subjects who agreed to a second year of double‐blind study drug administration ( N = 156). Results: Two‐year graft assessment was performed for 142 patients (80 aspirin patients, 62 ticagrelor patients, 425 total grafts), with an overall 2‐year graft occlusion rate of 10.6%. Vein graft occlusion at 2 years, the primary outcome of this study, did not significantly differ between the two groups (15.7% vs. 13.2%, aspirin vs. ticagrelor, p = .71). The incidence of vein grafts with any disease (stenosis or occlusion) did not significantly differ between the groups (19.4% vs. 19.8%, aspirin vs. ticagrelor, p = 1.00), and the number of patients with vein graft disease did not significantly differ between the groups (30.0% vs. 29.0%, aspirin vs. ticagrelor, p = 1.00). Vein grafts developing new disease did not significantly differ between the two groups (1.5% vs. 3.8%, aspirin vs. ticagrelor, p = .41). Freedom from major adverse cardiovascular events at 2 years was similar between the groups ( p = .75). Conclusion: Compared to conventional aspirin therapy, ticagrelor did not significantly reduce vein graft disease 2 years after CABG.